Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer
Aim: It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (ARneg), androgen-independent (AI) prostate cancer, which is an aggressive form of prostate cancer with limited treatment options. The goal of this study was to...
Saved in:
Main Authors: | Vignesh Sivaganesh (Author), Bela Peethambaran (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016) -
Androgen receptor overexpression in prostate cancer in type 2 diabetes
by: Stefan Zoltán Lutz, et al.
Published: (2018) -
Practical implications of androgen receptor inhibitors for prostate cancer treatment
by: Fabio Campodonico, et al.
Published: (2024) -
Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
by: Balaji Chandrasekaran, et al.
Published: (2023) -
Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene
by: Jindan Luo, et al.
Published: (2019)